The incidence and risk of cardiovascular events associated with pembrolizumab in patients with breast cancer

Cancer Lett. 2024 Sep 25:217277. doi: 10.1016/j.canlet.2024.217277. Online ahead of print.
No abstract available

Keywords: breast cancer; cardiotoxicity; cardiovascular events; immune checkpoint inhibitor; pembrolizumab.